Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer’s Disease Patients: A Systematic Review and Meta-Analysis

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

(2015) Rachelle S Doody et al.   Alzheimers Research & Therapy

Targeting Prodromal Alzheimer Disease With Avagacestat

(2015) Vladimir Coric et al.   JAMA Neurology

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

(2014) David B. Henley et al.   CURRENT MEDICAL RESEARCH AND OPINION

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat

(2012) Gary Tong et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects

(2012) Randy Dockens et al.   CLINICAL PHARMACOKINETICS

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers

(2012) Gary Tong et al.   CLINICAL THERAPEUTICS

Alzheimer's disease

(2011) Clive Ballard et al.   LANCET

Emerging role of Notch signaling in epidermal differentiation and skin cancer

(2010) John Panelos et al.   CANCER BIOLOGY & THERAPY

Non-melanoma skin cancer

(2010) Vishal Madan et al.   LANCET

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

(2010) David Moher et al.   International Journal of Surgery

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

(2008) Gordon K Wilcock et al.   LANCET NEUROLOGY

Inhibition and modulation of γ-secretase for Alzheimer’s disease

(2008) Michael S. Wolfe   Neurotherapeutics

Structure and function of γ-secretase

(2008) Alexandra Tolia et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY